Cardiac Outcome of Children With SARS-CoV-2 Related Multisystem Inflammatory Syndrome

Indian Pediatr. 2023 May 15;60(5):381-384. doi: 10.1007/s13312-023-2885-2. Epub 2023 Mar 20.

Abstract

Objective: To study the cardiac outcomes of patients with multisystem inflammatory syndrome in children (MIS-C) after 6-month of diagnosis.

Methods: This review of hospital records was conducted on MIS-C patients (aged <21 year) who completed a six-month follow up. The baseline demographic, clinical, laboratory, and treatment characteristics during the acute phase, and echocardiographic findings during follow-up were collected.

Results: 116 patients (61.2% male, median age 7 years) with MIS-C were included in the study. At the time of admission, cardiac abnormalities were present in 70.7% of MIS-C patients, and the most common cardiac abnormalities were valve failure (50.9%), followed by ventricular dysfunction (39.7%), and pericardial effusion (23.3%). Six month after diagnosis, cardiac abnormalities were found in 10.3% of patients, and patients had lower rates of ventricular dysfunction (P<0.001), valve failure (P<0.001), pericardial effusion (P<0.001), and coronary involvement (P<0.001) as composed to the baseline. Intravenous immunoglobulin (IVIG) and steroid treatment significantly reduced the odds of occurrence of ventricular dysfunction (P=0.002), valve failure (P=0.004), and low ejection fraction (P=0.002) in comparison to IVIG treatment.

Conclusion: While most MIS-C patients had abnormal echocardiographic findings at admission, only 10.3% of patients had cardiac abnormalities during follow up.

Publication types

  • Review

MeSH terms

  • COVID-19* / diagnosis
  • COVID-19* / therapy
  • Child
  • Child, Preschool
  • Echocardiography
  • Female
  • Heart Defects, Congenital*
  • Heart Valve Diseases
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Male
  • Pericardial Effusion
  • Steroids / therapeutic use
  • Stroke Volume
  • Systemic Inflammatory Response Syndrome* / diagnosis
  • Systemic Inflammatory Response Syndrome* / therapy
  • Ventricular Dysfunction

Substances

  • Immunoglobulins, Intravenous
  • Steroids

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related